154 related articles for article (PubMed ID: 9681081)
1. Effect of chemotherapy on carcinoma in situ of the testis.
Christensen TB; Daugaard G; Geertsen PF; von der Maase H
Ann Oncol; 1998 Jun; 9(6):657-60. PubMed ID: 9681081
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy is of limited efficacy in the control of contralateral testicular intraepithelial neoplasia in patients with testicular germ cell cancer.
Kleinschmidt K; Dieckmann KP; Georgiew A; Loy V; Weissbach L
Oncology; 2009; 77(1):33-9. PubMed ID: 19440001
[TBL] [Abstract][Full Text] [Related]
3. Management of testicular seminoma advanced disease. Report on 14 cases and review of the literature.
Porcaro AB; Antoniolli SZ; Maffei N; Beltrami P; Bassetto MA; Curti P
Arch Ital Urol Androl; 2002 Jun; 74(2):81-5. PubMed ID: 12161942
[TBL] [Abstract][Full Text] [Related]
4. Testis conserving chemotherapy in germ cell cancer: its potential to increase understanding of the biology and treatment of carcinoma-in-situ.
Oliver RT; Ong J; Berney D; Nargund V; Badenoch D; Shamash J
APMIS; 2003 Jan; 111(1):86-91; discussion 91-2. PubMed ID: 12752243
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy as an alternative to radiotherapy in the treatment of stage IIA and IIB testicular seminoma: a Spanish Germ Cell Cancer Group Study.
Garcia-del-Muro X; Maroto P; Gumà J; Sastre J; López Brea M; Arranz JA; Lainez N; Soto de Prado D; Aparicio J; Piulats JM; Pérez X; Germá-Lluch JR
J Clin Oncol; 2008 Nov; 26(33):5416-21. PubMed ID: 18936476
[TBL] [Abstract][Full Text] [Related]
6. Advanced seminoma: treatment results, survival, and prognostic factors in 142 patients.
Mencel PJ; Motzer RJ; Mazumdar M; Vlamis V; Bajorin DF; Bosl GJ
J Clin Oncol; 1994 Jan; 12(1):120-6. PubMed ID: 7505805
[TBL] [Abstract][Full Text] [Related]
7. Vinblastine, actinomycin D, bleomycin, cyclophosphamide and cis-platinum for advanced germ cell testis tumors: Brazilian experience.
Srougi M; Simon SD; de Góes GM
J Urol; 1985 Jul; 134(1):65-9. PubMed ID: 2409300
[TBL] [Abstract][Full Text] [Related]
8. Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours.
Fizazi K; Prow DM; Do KA; Wang X; Finn L; Kim J; Daliani D; Papandreou CN; Tu SM; Millikan RE; Pagliaro LC; Logothetis CJ; Amato RJ
Br J Cancer; 2002 May; 86(10):1555-60. PubMed ID: 12085204
[TBL] [Abstract][Full Text] [Related]
9. [Advanced germinal tumors of the testicle: clinical experience with cisplatin, bleomycin and vinblastine (PVB) or etoposide (BEP)].
Alonso Curbera G; González-Manzano R; Aramendía Beitia JM; Martínez Monge R; Agüera Fernández L; Rebollo Liceaga J
Rev Med Univ Navarra; 1993; 38(1):13-8. PubMed ID: 8711305
[TBL] [Abstract][Full Text] [Related]
10. An alternative treatment regimen of advanced seminoma with carboplatin, etoposide, and bleomycin instead of cisplatin-based therapy.
Giesen E; Mager A; van Tinteren H; Rodenhuis S; Kerst JM
Urol Oncol; 2013 Jan; 31(1):110-4. PubMed ID: 21458311
[TBL] [Abstract][Full Text] [Related]
11. Long-term results following adjuvant chemotherapy in patients with clinical stage I testicular nonseminomatous malignant germ cell tumors with high risk factors.
Böhlen D; Borner M; Sonntag RW; Fey MF; Studer UE
J Urol; 1999 Apr; 161(4):1148-52. PubMed ID: 10081858
[TBL] [Abstract][Full Text] [Related]
12. Late relapses (>2 years) in patients with stage I testicular germ cell tumors: predictive factors and survival.
Fedyanin M; Tryakin A; Kanagavel D; Bulanov A; Burova A; Figurin K; Fainshtein I; Sergeev U; Zakharova T; Garin A; Tjulandin S
Urol Oncol; 2013 May; 31(4):499-504. PubMed ID: 21803619
[TBL] [Abstract][Full Text] [Related]
13. Intratesticular effects of cisplatin-based chemotherapy.
Dieckmann KP; Loy V
Eur Urol; 1995; 28(1):25-30. PubMed ID: 8521890
[TBL] [Abstract][Full Text] [Related]
14. [Treatment of metastatic seminoma by chemotherapy.: an experience].
Komatsubara S; Itoi T; Watanabe M; Kitamura Y; Koike T
Nihon Hinyokika Gakkai Zasshi; 2000; 91(10-11):666-72. PubMed ID: 11109817
[TBL] [Abstract][Full Text] [Related]
15. Risk-adapted treatment for patients with clinical stage I nonseminomatous germ cell tumor of the testis.
Amato RJ; Ro JY; Ayala AG; Swanson DA
Urology; 2004 Jan; 63(1):144-8; discussion 148-9. PubMed ID: 14751368
[TBL] [Abstract][Full Text] [Related]
16. Patterns of relapse and treatment outcome after active surveillance or adjuvant carboplatin for stage I seminoma: a retrospective study of the Spanish Germ Cell Cancer Group.
Aparicio J; García Del Muro X; Maroto P; Terrasa J; Castellano D; Bastús R; Gumà J; Sagastibeltza N; Durán I; Ochenduszko S; Meana JA; García-Sánchez J; Arranz JA; Gironés R; Germà JR
Clin Transl Oncol; 2021 Jan; 23(1):58-64. PubMed ID: 32462393
[TBL] [Abstract][Full Text] [Related]
17. [Testis germ cell tumours: which chemotherapy, for which patients?].
Fléchon A; Droz JP
Ann Urol (Paris); 2007 Apr; 41(2):56-67. PubMed ID: 17486913
[TBL] [Abstract][Full Text] [Related]
18. [Management of advanced seminoma: retrospective study of 96 patients].
Bompas E; Fléchon A; Biron P; Droz JP
Bull Cancer; 2002 Oct; 89(10):877-85. PubMed ID: 12441279
[TBL] [Abstract][Full Text] [Related]
19. Management of stage II seminoma.
Warde P; Gospodarowicz M; Panzarella T; Catton C; Sturgeon J; Moore M; Jewett M
J Clin Oncol; 1998 Jan; 16(1):290-4. PubMed ID: 9440755
[TBL] [Abstract][Full Text] [Related]
20. Long-term followup results of 1 cycle of adjuvant bleomycin, etoposide and cisplatin chemotherapy for high risk clinical stage I nonseminomatous germ cell tumors of the testis.
Westermann DH; Schefer H; Thalmann GN; Karamitopoulou-Diamantis E; Fey MF; Studer UE
J Urol; 2008 Jan; 179(1):163-6. PubMed ID: 18001800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
